Avantor Q3 2026: Revenue Beats Estimates as Both Segments Return to Growth
As seen on the 24/7 Wall St. homepage on October 28, 2026.
Avantor's turnaround finally shows up in the numbers: both segments grew organically and management raised full-year organic revenue growth guidance to +0.75% to +1.25%, up from a range that started negative.
Continue ReadingShow less
Avantor posted Q3 2026 net sales of $1.70 billion, beating expectations on 5.2% organic growth.
Both operating segments grew organically for the first time in recent memory, with Bioscience and Medtech Products returning to growth.
Management raised full-year organic revenue growth guidance to +0.75% to +1.25%, up from a range that previously extended into negative territory.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
The company swung to GAAP net income of $203.40 million from a loss a year earlier, though leverage remains elevated.
CEO Emmanuel Ligner said the quarter exceeded internal expectations, giving investors a more concrete basis for judging whether the recovery holds.
Mentioned: AVTR